GlassScriptPhysician profile
Carmen A Alvarez
NPI 1508828906
$2,981.95
in general payments reported to CMS, 2019-2025
28 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $233 · 2020: $364 · 2021: $645 · 2022: $549 · 2023: $807 · 2024: $384.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,191.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,190.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $470.84 | 2020-2024 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $453.05 | 2019-2024 | Wegovy |
| Dexcom, INC. | $368.75 | 2021-2024 | Dexcom G6 Transmitter |
| Boehringer Ingelheim Pharmaceuticals, INC. | $222.52 | 2020-2023 | Jardiance |
| Ascensia Diabetes Care US INC. | $169.53 | 2023-2024 | |
| Sanofi-Aventis U.S. LLC | $123.53 | 2021-2024 | |
| Abbvie INC. | $113.92 | 2020-2024 | |
| Abbott Laboratories | $86.12 | 2022-2024 | Freestyle Libre 3 |
| Radius Health, INC. | $82.40 | 2019-2023 | |
| Medtronic, INC. | $82.29 | 2023-2024 | Minimed 780g |
| Janssen Pharmaceuticals, INC | $79.75 | 2020-2021 | |
| Amgen INC. | $77.07 | 2021-2023 | Prolia, Evenity |
| Astrazeneca Pharmaceuticals LP | $61.87 | 2020-2021 | |
| Amneal Pharmaceuticals LLC | $60.55 | 2021-2023 | Unithroid |
| Mannkind Corporation | $55.76 | 2023-2024 | Afrezza |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $53.37 | 2022-2023 | |
| Amarin Pharma, INC. | $51.51 | 2019-2021 | |
| Insulet Corporation | $49.68 | 2023 | Omnipod |
| Alexion Pharmaceuticals, INC. | $44.35 | 2023-2024 | Strensiq |
| Pfizer INC. | $43.37 | 2021-2022 | |
| Recordati_rare_diseases_inc. | $43.15 | 2021-2022 | |
| Tandem Diabetes Care, INC. | $41.92 | 2021-2023 | T:Slim X2 Insulin Pump With Control-Iq |
| Zealand Pharma US, INC. | $35.72 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $31.64 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $24.60 | 2020-2022 | |
| Eusa Pharma (US) LLC | $22.47 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $16.63 | 2021 | |
| Ibsa Pharma INC. | $15.59 | 2024 | Tirosint, Licart |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Carmen Alvarez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.